- Home
- ZLAB vs VRDN Comparison
ZLAB vs VRDN Comparison
Compare ZLAB & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | VRDN |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | VRDN |
|---|---|---|
| Price | $18.31 | $19.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $49.60 | $35.46 |
| AVG Volume (30 Days) | 714.0K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.46 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $460,156,000.00 | $5,706,000.00 |
| Revenue This Year | $9.75 | $13.73 |
| Revenue Next Year | $26.03 | $279.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $13.18 |
| 52 Week High | $39.64 | $34.29 |
Technical Indicators
Market Signals| Indicator | ZLAB | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 39.86 | 56.78 |
| Support Level | $16.84 | $17.54 |
| Resistance Level | $19.55 | $20.00 |
| Average True Range (ATR) | 0.76 | 0.76 |
| MACD | -0.25 | -0.03 |
| Stochastic Oscillator | 4.64 | 69.17 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.